In Canada, the patent for some semaglutide drugs has expired, paving the way for the country to become the first to offer ...

The global Generic Drugs Market is valued at USD 487.21 Billion in 2024 and is projected to reach a value of USD 898 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 5.75% between 2025 and ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

Danish drug maker Novo Nordisk is preparing to introduce a new version of its blockbuster drug Ozempic to compete with ...

Replacing high-cost generics with cheaper medications that have the same clinical benefit could have cut down spending and saved patients about 88%, according to Johns Hopkins research published in ...

Ozempic and Wegovy – two brand-name semaglutide drugs prescribed for diabetes and weight loss – will lose market exclusivity ...

Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health regulator for ...

All samples met Indian Pharmacopeia standards for drug content, dissolution, and impurities, with no meaningful quality ...

“When I worked at Cambrex, I learned that generics are kind of boring,” says Kenneth Drew, senior director of North American sales and business development at Flamma, an Italian manufacturer of active ...